to pneumococcal saccharides to prepare pneumococcal conjuolder children, it is generally held that they are inconsistently gate vaccines ) for clinical evaluation. Although immunogenic and ineffective in young children [4, 5] .
There has been long-standing interest in the prevention of
The great success of recent efforts to prevent Haemophilus influenzae type b infections by vaccination with conjugate vacpneumococcal infections by vaccination. A hexavalent, unconcines consisting of the capsular saccharide covalently joined to jugated capsular polysaccharide (PS) vaccine against Streptoa protein carrier [6] has spurred development of pneumococcal coccus pneumoniae intended for use in children was marketed saccharide conjugate vaccines. As was the case for H. influenby Squibb in 1946 [1, 2] but withdrawn in 1954 when antimizae type b conjugate vaccines, pneumococcal conjugate vaccrobial therapy was believed to have diminished the need for cines prepared for clinical trials differ in the carrier protein disease prevention. Subsequently, the observation by Austrian used, the saccharide molecular size, and the method of conjuand Gold [3] that mortality in adults remained high despite gating the saccharide to the protein. early antimicrobial therapy [3] led to the licensure of 14-valent One protein carrier used in the manufacture of an H. influand, subsequently, 23-valent unconjugated capsular PS vacenza type b vaccine (HbOC) is a cross-reacting mutant diphthecines. While several studies have suggested these vaccines have ria toxin molecule called CRM 197. This protein has been linked a role in preventing pneumococcal infections in adults and to pneumococcal saccharides to prepare pneumococcal conjuolder children, it is generally held that they are inconsistently gate vaccines (Pn-CRM 197 ) for clinical evaluation. Although immunogenic and ineffective in young children [4, 5] .
the immunogenicity of the type 6B component was minimal, the recent demonstration that a bivalent vaccine consisting of 2 pneumococcal polysaccharides, types 6B and 23F, separately conjugated to CRM 197 was immunogenic and well tolerated in Received 16 October 1996; revised 28 February 1997. toddlers [7] prompted interest in the evaluation of the safety should be present for optimal immunogenicity has not received ‡ % experiencing adverse event significantly (P õ .002) exceeded that for evaluation in young infants. Also, if a pneumococcal vaccine any pneumococcal conjugate vaccine group. § In subjects not receiving simultaneous pneumococcal conjugate vaccine.
were introduced into clinical practice, it would be convenient to administer it at visits where other vaccines are currently recommended for administration. Therefore, it would be of To study these issues, we evaluated the safety and immunogenicity of several pentavalent Pn-CRM 197 vaccines that difinterest to know whether children who received a Pn-CRM 197 vaccine had acceptable serum antibody responses to diphtheria fered in the quantity of saccharide per dose and the chain length of the saccharide moiety in a population of healthy US infants. and tetanus toxoids and the serotype b capsule of H. influenzae. Figure 1 . Anticapsular antibody against serotype 6B Streptococcus pneumoniae -CRM 197 conjugates. Geometric mean anticapsular antibody concentration (GMC) for each of 6 type 6B conjugate formulations is plotted on y axis; age at each immunization is plotted on x axis. At 4 months, GMC for all type 6B conjugate formulations decreased significantly (P Å .0001) relative to GMC at previous visit. At 6 months, GMC did not change significantly relative to GMC at previous visit for any of type 6B formulations; however, at 7 months, GMC for all formulations increased significantly (P Å .0001) relative to GMC at previous visit. PS Å polysaccharide; OS Å oligosaccharide. Nos. following PS-and OS-refer to saccharide dose in mg. Geometric mean anticapsular antibody concentration (GMC) for each of 6 type 14 conjugate formulations is plotted on y axis; age at each immunization is plotted on x axis. At 4 months, GMC decreased significantly (P £ .007) relative to GMC at previous visit for all formulations except 5-mg (P Å .76) and 2-mg (P Å .16) polysaccharide (PS) formulations. At 6 and 7 months, GMC increased significantly (P £ .002 and Å .0001 for 6 and 7 months, respectively) relative to GMC at previous visit for all formulations. OS Å oligosaccharide. Nos. following PS-and OS-refer to saccharide dose in mg. 
Materials and Methods
Kentucky Pediatric Research). Subjects were randomized into 7 groups for immunization at 2, 4, and 6 months of age. Groups Vaccines. Two types of pentavalent pneumococcal saccharide 1 -6 received one of the six pentavalent pneumococcal conjuconjugate vaccines were used. Both contained capsular saccharides gate vaccine formulations. Group 7 (controls) did not receive a from serotypes 6B, 14, 18C, 19F, and 23F. In one, the capsular pneumococcal vaccine. All subjects were given HbOC/diphthematerial from each serotype was an OS of defined length. In the ria -tetanus toxoids -pertussis vaccine (HbOC/DTP, Tetramune; other, capsular PS from serotypes 6B, 14, 19F, and 23F and the Lederle Laboratories, Pearl River, NY) intramuscularly in a OS from serotype 18C formulated the vaccine, which we desigseparate syringe at a separate site (anterior thigh) and oral polio nated PS conjugate vaccine.
vaccine (OPV, Orimune; Lederle Laboratories) at the same visit. The OS-CRM 197 conjugates were synthesized by either first hy-
The parents of children receiving HbOC/DTP and a pneumococdrolyzing the native PS to smaller fragments and then subjecting cal conjugate vaccine were blinded as to the site of administrathe fragments to limited periodate oxidation or by oxidizing the tion of the two vaccines. native PS and then hydrolyzing it into smaller fragments. The Blood samples were obtained prior to the three immunizations PS-CRM 197 conjugates were synthesized by oxidizing native pneuand 1 month after the third immunizations, when the infants were mococcal PS with sodium metaperiodate to introduce random alde-7 months old. Serum was separated from blood, stored at 020ЊC hyde functional groups. Oxidized OS or PS fragments were couor 070ЊC, and shipped to Lederle-Praxis (West Henrietta, NY) on pled to CRM 197 in the presence of sodium cyanoborohydride, dry ice. a reductive amination similar to that used in the preparation of Children were observed for 30 min following each immunization, HbOC [12] . and parents were requested to record, on a standardized form, informaThe pentavalent vaccines were a mixture of the individual serotion regarding the presence and magnitude of fever ( §38.4ЊC), erythema, and induration or tenderness at a site of immunization. Parents type saccharide-protein conjugates. For each pneumococcal sero-
06-27-97 16:13:10 jinfal UC: J Infect Geometric mean anticapsular antibody concentration (GMC) for each of 6 type 18C conjugate formulations is plotted on y axis; age at each immunization is plotted on x axis. At 4 months, GMC increased significantly (P £ .03) relative to GMC at previous visit for all formulations except 0.5-mg oligosaccharide (OS) (P Å .28). At 6 and 7 months, GMC increased significantly (P Å .0001 and £ .007 for 6 and 7 months, respectively) relative to GMC at previous visit for all formulations. PS Å polysaccharide. Nos. following PS-and OS-refer to saccharide dose in mg.
were contacted by study personnel at 24 and 72 h after each immunit tests. Proportions were compared by use of x 2 tests or, when appropriate, Fisher's exact test. Statistical software (Statview; zation to ensure recording of the relevant data.
Antibody assays. IgG antibody to each pneumococcal saccha-(Abacus Concepts, Berkeley, CA) was used for all calculations. For comparisons, P õ .05 was considered significant. ride contained in the vaccine was measured at Lederle-Praxis by ELISA after preabsorption with cell wall PS as previously described [13] . Specimens were encoded to ensure blinding of laboraResults tory personnel. The serotype-specific antibody concentration was expressed in micrograms per milliliter relative to human anti-pneuSubjects. Four hundred infants with a mean age of 2.2 mococcal standard serum (lot 89-S; Center for Biological Evaluamonths (range, 1.4 -3.3) at entry were enrolled in the study. tion and Review, US Food and Drug Administration, Rockville,
The mean age at the second vaccination was 4.3 months (range, MD) [10] . Antibody to the serotype b capsule of H. influenzae 2.9 -8.3), and at the third vaccination it was 6.4 months (range, type b was quantitated by an ELISA previously characterized at 4.9 -10.8). Three hundred fifty patients (88%) completed the 15] . Antibodies to tetanus and diphtheria toxstudy protocol. Reasons for withdrawal included adverse events oids were determined by ELISA. For both, the relevant toxoid was associated with vaccine administration (7 infants total: highused to coat polystyrene microtiter plates. Bound antibody was pitched, unusual cry [4] , inconsolable cry [1] , persistent crying detected with goat anti-human IgG coupled to alkaline phosphatase, and p-nitrophenyl phosphate was used to quantitate bound for ú3 h [1] , hypotonic and hyporresponsive episode [1] ), enzyme. Absorbance was compared with that for reference sera:
parental request (11 infants), noncompliance (31 infants), and H89-F for tetanus toxoid (assigned value, 55 IU/mL) and C587769 culture-proven pertussis (1 infant). Ten subjects were hospitalfor diphtheria toxoid (assigned value, 0.3 IU/mL). The lower limit ized during the study period. Discharge diagnoses included of detection was 0.001 U/mL for anti-tetanus toxoid antibodies otitis media (1 infant), reactive airway disease (2 infants; 1 and 0.001 IU/mL for anti-diphtheria toxoid antibodies. Geometric mean anticapsular antibody concentration (GMC) for each of 6 type 19F conjugate formulations is plotted on y axis; age at each immunization is plotted on x axis. At 4 months, GMC decreased significantly (P Å .0001) relative to GMC at previous visit for all formulations except for all type 19F polysaccharides (PS) (P § .14). For PS conjugate formulations at 6 and 7 months, GMC significantly (P Å .0001) increased. In contrast, at 6 months, oligosaccharide (OS) conjugate formulations did not change significantly relative to GMC at previous dose. However, at 7 months, GMC for all conjugate formulations uniformly increased significantly (P £ .01) relative to GMC at previous dose except for 2-mg PS vaccine (P Å .05). Nos. following PS-and OS-refer to saccharide dose in mg.
creased rate of fever with increasing dose occurred in the pneuImmunogenicity. Irrespective of saccharide dose and chain length, 1 month after receipt of a 3-dose regimen of a pneumomococcal vaccine recipients: After the third dose of HbOC/ DTP / Pn-CRM 197 (administered to infants at 6 months of coccal conjugate vaccine, the mean anticapsular antibody concentration exceeded that found in pneumococcal vaccine -naive age), the rate was significantly higher than that occurring at 2 and 4 months of age and also higher compared with rates for control infants (figures 1 -5). controls, who received HbOC/DTP only (table 1). Temperature
The pattern of appearance of antibody differed according to §39.1ЊC occurred in subjects after 22 (2.0%) of 1127 administhe serotype administered and the saccharide chain length. For tered doses. There was no pattern observed with respect to the serotype 6B conjugate vaccines (figure 1), the first and receipt of any of the pneumococcal vaccines, group, or dose second doses elicited mean antibody concentrations that did number.
not differ from those of controls. Only after the third dose did the mean antibody concentration in the pneumococcal vaccine When summed across dose number and stratified by vaccine regimen (table 2), erythema was significantly more frequent at recipients exceed that measured in the control infants. For the serotype 14 conjugates (figure 2), the first dose elicited a mean sites where HbOC/DTP was administered than at the site of any pneumococcal conjugate vaccine. The rate of erythema did antibody concentration that did not differ from that of controls, but the mean concentrations after the second and third doses not change with dose number for any of the vaccine regimens, although erythema was significantly more frequent at sites did. For the serotype 18C OS-conjugates (figure 3), with the exception of OS-0.5, a statistically significant (P £ .03) inwhere the pneumococcal OS conjugate vaccine containing 0.5 mg of each saccharide (OS-0.5) was administered than at sites crease in anticapsular antibody occurred after each dose. For the serotype 19F conjugate vaccines (figure 4), the mean reof administration of the PS-5 vaccine. Similarly, induration and tenderness were more frequent at sites where HbOC/DTP sponse differed when stratified according to the saccharide administered. Among those receiving the 19F PS conjugates, the was administered, and the rate of induration at the sites of the OS-5.0 (containing 5 mg) and the OS-0.5 pneumococcal mean anticapsular response after the first dose did not differ from that documented prior to immunization, but significant conjugates exceeded that occurring at sites where the PS-5 vaccine was administered.
(P £ .01) increases occurred after the second and third doses.
/ 9d2f$$au23 06-27-97 16:13:10 jinfal UC: J Infect Figure 5 . Anticapsular antibody against serotype 23F S. pneumoniae -CRM 197 conjugates. Geometric mean anticapsular antibody concentration (GMC) for each of 6 type 23F conjugate formulations is plotted on y axis; age at each immunization is plotted on x axis. At 4 months, GMC decreased significantly (P Å .0001) relative to GMC at previous visit for all formulations. At 6 and 7 months, GMC increased significantly (P £ .001 and £ .0001 for 6 and 7 months, respectively) relative to GMC at previous visit for all formulations. PS Å polysaccharide; OS Å oligosaccharide. Nos. following PS-and OS-refer to saccharide dose in mg.
In contrast, among those receiving the 19F OS conjugates, the A detailed analysis of anticapsular antibody responses to the PS-5 formulation is presented in table 3. The mean fold increase mean antibody concentration significantly declined after the first dose and increased only after the third dose. For the serofor pneumococcal anticapsular antibody in serum obtained from the control infants 1 month after the third immunization type 23F conjugates (figure 5), the pattern of response resembled that occurring among recipients of the serotype 14 conjuranged from 0.10 to 0.15 for the 5 serotypes contained in the pneumococcal conjugate vaccines. These values reflected a net gate vaccines.
In general, PS formulations were more immunogenic than decline from antibody concentrations measured in serum obtained at the first immunization visit, presumably indicating OS formulations of the same dose level, although the difference was not always significant (figure 6). For the OS type decay of maternal antibody. For recipients of the PS-5 vaccines, the mean fold increases 1 month after the third immunization 18C conjugates, no significant difference was noted in the mean anticapsular antibody response whether the type 18C OS was visit were 2.7, 18.9, 13.4, 7.7, and 15.1 for serotypes 6B, 14, 18C, 19F, and 23F, respectively. These mean fold increases a component of the PS or the OS conjugate vaccines.
Following three doses of pneumococcal conjugate vaccine, were all significantly greater than those calculated for the control infants. Similar data were obtained for the PS-2 conjugate the mean anticapsular antibody concentrations varied significantly when stratified by serotype (P õ .0001, analysis of vaccines. The proportion of children with an anticapsular antibody variance). The mean concentration of anticapsular antibody directed against the capsular PSs of serotypes 14 and 19F concentration exceeding 0.15 and 1.0 mg/mL in serum obtained Ç1 month after the third dose of vaccine uniformly exceeded exceeded all others (P õ .001, unpaired t test). Serotype 6B conjugate vaccines were the least immunogenic (P õ .001, that in the control infants (table 3) . Anti -tetanus toxoid antibody was assayed in serum obtained unpaired t test); types 18C and 23F were intermediate.
For the PS vaccines, a relationship was noted between the prior to immunization and 1 month after receipt of the third dose from subjects receiving the PS-2 vaccine and the control saccharide content (dose level) and the magnitude of the anticapsular antibody response. For 4 of the 5 serotypes, the mean subjects. Prior to immunization, the geometric mean anti -tetanus toxoid antibody concentrations were 0.86 IU (95% confiantibody response for the PS-5 vaccine was the highest (figure 6), but, for any serotype, this mean did not differ significantly dence interval [CI], 0.58 -1.28) and 0.77 IU (95% CI, 0.53 -1.13) for PS-2 and control subjects, respectively, values that did from that elicited by the pneumococcal conjugate PS vaccine containing 2 mg of each saccharide (PS-2). not differ significantly. One month after the third immunization / 9d2f$$au23 06-27-97 16:13:10 jinfal UC: J Infect visit, when infants were 7 months old, the values were 8.99 this result would have been expected since a relationship between immunogenicity and saccharide molecular mass estab-IU (95% CI, 6.38 -12.68) and 8.49 IU (95% CI, 6.17 -11.69), lished for the dextran elaborated by Leuconostoc mesenteroides respectively, a difference that was also not significant. [18, 19] has been presumed to extend to other PSs. Indeed, PSs For anti -diphtheria toxoid antibody, the geometric means of presumably sufficiently large size to function as effective prior to immunization were 0.07 IU (95% CI, 0.05 -0.09) and immunogens from Salmonella typhi [20] , H. influenzae type b 0.05 IU (95% CI, 0.03 -0.07) for PS-2 and control subjects, [21] , S. pneumoniae [22] , and Neisseria meningitidis [23] have respectively, values that did not differ significantly. One month provided protection, at least in certain populations. The relaafter the third immunization visit, when infants were 7 months tionship between chain length and immunogenicity is undoubtold, the means were 1.70 IU (95% CI, 1.30 -2.33) and 1.07 edly more complex for conjugate vaccines, with which as few IU (95% CI, 0.80 -1.43), respectively, a significant (P Å .02) as two repeating units of carbohydrate can evoke an immune difference; all subjects had values ú0.05 and 0.01 U/mL, antiresponse. Conformation of the saccharide moiety, availability body concentrations said to be protective against diphtheria of antigenic structural components, and site(s) of saccharide [16] and tetanus [17] , respectively. attachment to protein carriers are among the factors, in addition The geometric mean serum antibody directed at the capsular to chain length, that may influence the immune response [9] . serotype of type b H. influenzae (anti-PRP) was higher for
The mean concentration of anticapsular antibody elicited by each group of pneumococcal vaccine recipients than for control the PS vaccines in infants at 7 months of age varied according infants who received HbOC/DTP alone (table 4); this was an to the serotype; the geometric mean ranged from 1.24 mg/mL unexpected finding. The mean for each group significantly (P for type 6B to 3.87 mg/mL for type 14. The implication of £ .03) exceeded that for the control children with the single these data for protection from invasive disease is uncertain exception of PS-5, for which the mean was 3.80 mg/mL and because the antibody concentration necessary to infer protecthe same trend was observed, but the difference was not sigtion is not known with certainty. Using a model of experimental nificant (P Å .07).
type 6B pneumococcal bacteremia in mice and rats, Rubin et al. [24] suggested that 0.06 -0.09 mg/mL anticapsular antibody was associated with protection. Saladino et al. [25] calculated Discussion a minimum protective serum antibody concentration for type Our data demonstrate that the pentavalent pneumococcal sac-6B that was somewhat higher (0.12 -0.54 mg/mL). charide conjugate vaccines elicited mean anticapsular antibody
The mean anticapsular antibody concentration produced by concentrations that exceeded those occurring in unimmunized PS-5 and PS-2 exceeded these estimates of protective efficacy controls, irrespective of saccharide length or quantity of antiby several fold. For serotypes 18C, 19F, and 23F, the protective gen. As expected, the vaccines were safe; no major untoward concentration estimates of Saladino et al. [25] were 0.9, effects were documented. Minor differences in rates of adverse 0.55 -2.9, and 0.27 mg/mL, respectively. Geometric mean antireactions between groups likely reflected a errors.
body concentrations well in excess of these estimates were The PS conjugate vaccines were more immunogenic than also produced by the corresponding PS-5 and PS-2 serotypespecific vaccine components. The mean estimates of 2.6 -13.0 their OS counterparts. For unconjugated capsular PS vaccines, [26] . If protection could have been extended to serotypes that were immunologically related to the 5 serotypes tion will require clarification.
Relating the concentration of circulating antibody to proteccontained in the vaccine studied herein, then 77.3% (California) and 74.0% (Connecticut) of the invasive infections could have tive surrogates for pneumococcal conjugate vaccines may be a complex task. For saccharide-protein conjugate vaccines been prevented. Similar considerations will undoubtedly apply to the prevention of otitis media. For example, the 5 serotypes against H. influenzae type b, it has been appreciated that protection against disease probably occurs by three mechanisms: (1) contained in the pneumococcal conjugate vaccines we studied caused 46% of the cases of symptomatic otitis media in children provision of circulating anticapsular antibody to the vaccinee, (2) decrease in pharyngeal, asymptomatic carriage among vac- [35] . If protection had been accorded to immunologically related serotypes, then 56% of cases could have been prevented. cinees with implied decreased circulation of the bacterium, and (3) the apparent ability of these vaccines to prime for an While the importance of conjugate vaccine priming in protecting a vaccinated host is uncertain, it is of interest to specuanamnestic response to unconjugated capsular PS vaccine and, by inference, to native capsular PS when presented on the late whether a three-dose schedule (e.g., at 2, 4, and 6 months of age) is necessary to achieve this effect or whether fewer surface of the bacterium. Thus, consideration of the anticapsular response is important but may be limited in terms of direct doses might suffice. The implications of this question relate to decreasing the number of needle sticks for a child to be ''upextrapolation to protection of vaccinated hosts. With parental consent, it is our intention to offer a dose of unconjugated to-date,'' to the development of combination vaccines that minimize the likelihood of antigenic interference and to decreasing pneumococcal PS vaccine to the recipients of the pneumococcal conjugate vaccines, the hypothesis being that they may have an the cost of a vaccination program, an issue particularly important in some developing countries. Our study was not deanamnestic response to the serotypes contained in the conjugate vaccines since they have been primed by the regimens designed to address whether fewer than three doses are sufficient to render a subject ''primed.'' However, from the data in figscribed in this trial.
Which of the 90 pneumococcal serotypes should be repreures 1 -5, one might infer that the number of doses of conjugate vaccine required for priming may vary by serotype in the pentasented in a pneumococcal vaccine suitable for use in young infants? The distribution of serotypes that cause invasive disvalent vaccines we studied. A study designed to address this question a priori could clarify this interesting and important ease in young children [26 -30] and otitis media [31 -35] differ. Moreover, differences in the serotypes of invasive disease isoissue. The finding of a higher mean anti-PRP antibody response lates in developed and developing countries suggest that it may be necessary to formulate different vaccines for use in different in the children who received the Pn-CRM 197 conjugates is of obvious interest but will require further study. These differpopulations. The 5 serotypes of S. pneumoniae that comprised the vaccines we evaluated were chosen with the help of data ences are unlikely to reflect a error since they were observed / 9d2f$$au23 06-27-97 16:13:10 jinfal UC: J Infect 
